Your session is about to expire
← Back to Search
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma/Chronic Lymphocytic Leukemia
Study Summary
This trial will evaluate the safety of CAR20.19.22 T-cells in patients with B-cell non-Hodgkin lymphoma (NHL) / chronic lymphocytic leukemia (CLL).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the most hazardous amount of CAR20.19.22 cells that can be administered to patients?
"Our analysis yields a rating of 1 for the safety profile of Dose Expansion: The maximum tolerated dose of CAR20.19.22 cells; this is due to it being in its introductory testing phase, wherein there are not many studies that back up its efficacy or safe usage."
Are there any vacancies available for potential participants of this research?
"Affirmative. According to records found on clinicaltrials.gov, this medical research project is currently enrolling individuals for participation. The study was first uploaded onto the database on June 30th 2022 and then amended most recently on July 1st 2022. At present, 36 volunteers are sought across one location."
How many participants have been enrolled in this research endeavor?
"Affirmative. Clinicaltrials.gov records confirm that this medical analysis, which was initially posted on June 30th 2022 is currently enrolling participants. 36 patients are needed from a single research site for the study to be successful."
Share this study with friends
Copy Link
Messenger